Clinical trials: Kidney (Renal Cell) Cancer
Clear Cell Renal Cell Carcinoma, VHL Syndrome
Overtaking Intra and Inter Tumoral Heterogeneity In Von Hippel-Lindau Related Renal Cancer
The goal of this study is to comprehensively map intra and inter tumor heterogeneity of ccRCC in VHL patients through the use of imaging, molecular biology and genomics techniques.
- Trial name
- ITHORinVHL (NCT06195150)
- Testing
- Blood collection
- Where
- Italy
- Volunteers
- 3 people
- Sponsor
- IRCCS San Raffaele
Renal Cell Carcinoma
Neoadjuvant Pembrolizumab and Lenvatinib for Renal Cell Carcinoma
This study will evaluate the effect of investigational drugs, pembrolizumab alone or pembrolizumab with lenvatinib, on the immune systems response to kidney cancer when given before and after surgery to remove kidney cancer.
- Trial name
- NCT05733715
- Testing
- Pembrolizumab infusion, Lenvatinib tablet
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Abramson Cancer Center at Penn Medicine
Clear Cell Renal Cell Carcinoma
68Ga-NYM096/177Lu-NYM096 in Metastatic ccRCC
This is a single-center, phase I study. Patients with metastatic clear cell renal cell carcinoma will be recruited in this study to (Phase A) evaluate using 68Ga-NYM096 PET/CT and to (Phase B) treat with 177Lu-NYM096.
- Trial name
- NYCRRLT (NCT06649682)
- Testing
- 68Ga-NYM096 PET/CT and 177Lu-NYM096
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Peking Union Medical College Hospital
Non-Small Cell Lung Carcinoma, Breast Cancer
A Study of V934/V935 Vaccine in Cancer Participants With Selected Solid Tumors (V934-002)
This is a two-part study to test the safety, tolerability, and immune response for V934/V935 vaccine using a new prime-boost regimen in participants with selected solid tumors.
- Conditions
- Non-Small Cell Lung Carcinoma, Breast Cancer, Melanoma, Upper GI Tract Carcinoma
- Trial name
- NCT00753415
- Testing
- V935, V934-EP
- Volunteers
- 37 people
- Sponsor
- Merck Sharp & Dohme LLC
Metastatic Renal Cell Carcinoma, Metastatic Clear-cell Renal Cancer
Immunotherapy Study for Metastatic Renal Cell Cancer
In this Phase 1 Trial investigators plan to establish the MTD of HyperAcute®-Renal (HAR) immunotherapy in subjects with clinically metastatic renal cell carcinoma.
- Conditions
- Metastatic Renal Cell Carcinoma, Metastatic Clear-cell Renal Cancer, Recurrent Renal Cell Carcinoma, Refractory Renal Cell Carcinoma
- Trial name
- NCT02035358
- Testing
- HyperAcute®-Renal (HAR) Immunotherapy
- Where
- 3 sites in United States
- Volunteers
- 18 people
- Sponsor
- NewLink Genetics Corporation
Clear Cell RCC
Perioperative Trial With IO/TKI for Multi-stage Clear Cell Renal Cell Carcinoma
The IO/TKI regimens which combines Immune checkpoint inhibitors (IO) with Tyrosine Kinase Inhibitors (TKI) have become the standard first-line option for advanced ccRCC.
- Trial name
- TRIPLE-PATH (NCT07571551)
- Testing
- Toripalimab, Lenvatinib
- Where
- China
- Volunteers
- 75 people
- Sponsor
- Jinling Hospital, China
Kidney Cancer
High-Dose Intravenous Interleukin-2 in Treating Patients With Metastatic Renal Cell Carcinoma (Kidney Cancer) That Has Not Responded to Previous Low-Dose Intravenous or Subcutaneous Interleukin-2
RATIONALE: Interleukin-2 may stimulate a person's white blood cells to kill renal cell carcinoma (kidney cancer) cells. PURPOSE: This phase II trial is studying how well high-dose intravenous interleukin-2 works in treating…
- Trial name
- NCT00080977
- Testing
- aldesleukin
- Where
- United States
- Sponsor
- Blumenthal Cancer Center at Carolinas Medical Center
Kidney Cancer
Sunitinib and Surgery in Treating Patients With Localized or Metastatic Kidney Cancer
RATIONALE: Sunitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Trial name
- NCT00849186
- Testing
- sunitinib malate, neoadjuvant therapy, therapeutic conventional surgery
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Roswell Park Cancer Institute
Advanced Clear Cell Renal Cell Carcinoma
A Clinical Study of 6MW3211 in Patients With Renal Cancer
single arm, non-randomized, multicenter, open label, phase 2 clinical trial in patients with advanced clear cell renal cacer
- Trial name
- NCT05440045
- Testing
- 6MW3211
- Volunteers
- 30 people
- Sponsor
- Mabwell (Shanghai) Bioscience Co., Ltd.
Renal Cell Carcinoma, Ovarian Cancer
A Clinical Research About CD70-targeted CAR-T in the Treatment of CD70-positive Advanced/Metastatic Solid Tumors
This is a single-center, double-arm, open-label study. this study plans to evaluate the safety and efficacy of CD70-targeting CAR-T cells in the treatment of CD70-positive advanced/metastatic solid tumors, and obtain recommended…
- Conditions
- Renal Cell Carcinoma, Ovarian Cancer, Cervix Cancer, Metastatic Cancer
- Trial name
- NCT06010875
- Testing
- CD70 CAR-T cells
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Chongqing Precision Biotech Co., Ltd
Neoplasm Malignant, Renal Cell Carcinoma
A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid Tumors
This is a Phase 1, open-label, dose-escalation and expansion study, evaluating the safety, tolerability, pharmacokinetics (PK), preliminary antitumor activity, and effect on biomarkers of XL092 administered alone, in combination…
- Conditions
- Neoplasm Malignant, Renal Cell Carcinoma, Hormone Receptor Positive Breast Carcinoma, Metastatic Castration-resistant Prostate Cancer
- Trial name
- STELLAR-001 (NCT03845166)
- Testing
- XL092, Atezolizumab, Avelumab
- Where
- 86 sites in United States, Australia and 8 more
- Volunteers
- 325 people
- Sponsor
- Exelixis
Renal Cell Carcinoma, Nasopharyngeal Carcinoma
Trial of PRO1160 (GEN1160) in Relapsed or Refractory Non-Hodgkin Lymphoma (NHL) (PRO1160-001)
Brief Summary: This study will test the safety, including side effects, and determine the characteristics of a drug called GEN1160 (PRO1160) in participants with solid tumors and blood cancers.
- Conditions
- Renal Cell Carcinoma, Nasopharyngeal Carcinoma, Non Hodgkin Lymphoma
- Trial name
- NCT05721222
- Testing
- GEN1160
- Where
- 17 sites in United States, China
- Volunteers
- 42 people
- Sponsor
- Genmab
Kidney Cancer
Sunitinib Malate in Treating Patients With Kidney Cancer
RATIONALE: Sunitinib malate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Trial name
- NCT00943839
- Testing
- sunitinib malate, laboratory biomarker analysis, pharmacological study
- Where
- France
- Volunteers
- 60 people
- Sponsor
- Centre Antoine Lacassagne
Renal Cell Carcinoma, Soft Tissue Sarcoma
Study of the Pan-DAC Inhibitor AR-42 and Pazopanib in Advanced Sarcoma and Kidney Cancer
This phase 1 study was developed to identify recommended phase 2 doses (RP2Ds) of AR-42 and pazopanib when given in combination for subsequent clinical trials and may have potentially identified candidate pharmacodynamic and…
- Conditions
- Renal Cell Carcinoma, Soft Tissue Sarcoma, Metastatic Disease
- Trial name
- NCT02795819
- Testing
- AR-42, Pazopanib
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Virginia Commonwealth University
Kidney Neoplasm
[18F]Fluciclatide PET Imaging of Pazopanib Response
Positron emission tomography (PET) is a non-invasive imaging tool for monitoring functional and metabolic responses of biological events with specific radiotracer in vivo.
- Trial name
- NCT01961583
- Testing
- 18F-Fluciclatide
- Where
- South Korea
- Volunteers
- 12 people
- Sponsor
- Asan Medical Center
Cancer
Early Intervention vs. Standard Palliative Care in Improving End-of-Life Care in Advanced Cancer Patients
RATIONALE: Palliative care may help patients with advanced cancer live more comfortably. PURPOSE: This randomized clinical trial is studying an early intervention palliative care program to see how well it works compared to a…
- Trial name
- NCT00253383
- Testing
- counseling intervention, educational intervention, psychosocial assessment and care
- Where
- 2 sites in United States
- Volunteers
- 329 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
Renal Cell Cancer
Prediction of Response to Kinase Inhibitors Based on Protein Phosphorylation Profiles in Tumor Tissue From Advanced Renal Cell Cancer Patients
The rapid development of agents blocking kinases has established the use of molecularly targeted therapy as the preferred treatment approach for patients with metastatic renal cell cancer (RCC).
- Trial name
- NCT02071719
- Where
- Netherlands
- Volunteers
- 6 people
- Sponsor
- M. Labots
Renal Cell Carcinoma
Study on the Utilization of Cabozantinib in Adult Patients With Advanced or Metastatic Renal Cell Carcinoma (RCC) in 2nd Line Treatment Following Prior Vascular Endothelial Growth Factor (VEGF)-Targeted Therapy Under Real-real Life Clinical Setting in France.
The purpose of the protocol is to assess the Overall Survival (OS) at 1 year in patients after cabozantinib initiation.
- Trial name
- CAROLINE (NCT04609800)
- Sponsor
- Ipsen
Multiple Myeloma
Daratumumab in Combination With Bortezomib and Dexamethasone in Subjects With Relapsed or Relapsed and Refractory Multiple Myeloma and Severe Renal Impairment
Myeloma patients with renal impairment need a rapid and effective reduction of tumor burden to enable renal recovery, which is correlated with prognosis of the patients.
- Trial name
- GMMG-DANTE (NCT02977494)
- Testing
- Daratumumab, Bortezomib, Dexamethasone
- Where
- 10 sites in Germany, Greece
- Volunteers
- 22 people
- Sponsor
- Universitätsklinikum Hamburg-Eppendorf
Metastatic Renal Cell Carcinoma, Stage IV Renal Cell Cancer AJCC v8
Focused Radiation Versus Systemic Therapy for Kidney Cancer Patients With Limited Metastasis, SOAR Study
This phase III trial compares the effect of stero-ablative radiotherapy (SAbR) followed by standard of care systemic therapy, to standard of care systemic therapy alone, in patients with kidney cancer that has spread from where…
- Trial name
- NCT05863351
- Testing
- Computed Tomography, Magnetic Resonance Imaging, Questionnaire Administration
- Where
- 108 sites in United States
- Volunteers
- 472 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.